garenoxacin has been researched along with Infections, Staphylococcal in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, DL; Drusano, GL; Liu, W; Louie, A; Rice, LB | 1 |
| Brandenburg, K; Grüger, T; Reiners, AL; Schnitzler, N; Zündorf, J | 1 |
| Drlica, K; Eisner, W; Kreiswirth, B; Perl-Rosenthal, N; Zhao, X | 1 |
| Andes, D; Craig, WA | 1 |
| Entenza, JM; Glauser, MP; Moreillon, P; Vouillamoz, J | 1 |
| Brown, DL; Deshpande, L; Deziel, M; Drusano, GL; Fritsche, TR; Jones, RN; Leary, R; Liu, W; Louie, A; Tam, VH | 1 |
| Bast, DJ; de Azavedo, JC; Duncan, CL; Kreiswirth, BN; Low, DE; McGeer, A; Muller, M; Pong-Porter, S; Willey, BM | 1 |
7 other study(ies) available for garenoxacin and Infections, Staphylococcal
| Article | Year |
|---|---|
Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus.
Topics: Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Quinolones; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2009 |
Garenoxacin-induced increase of CD11b expression on human polymorphonuclear neutrophils does not affect phagocytosis and killing of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; CD11b Antigen; Colony Count, Microbial; Flow Cytometry; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Neutrophils; Phagocytosis; Quinolones; Respiratory Burst; Staphylococcal Infections; Staphylococcus aureus; Up-Regulation | 2011 |
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Indoles; Microbial Sensitivity Tests; Mutation; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus aureus | 2003 |
Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Bacterial Infections; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Klebsiella Infections; Klebsiella pneumoniae; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Muscle, Skeletal; Pneumococcal Infections; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Endocarditis, Bacterial; Floxacillin; Fluoroquinolones; Infusions, Intravenous; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Rats; Staphylococcal Infections; Streptococcal Infections; Vancomycin; Viridans Streptococci | 2004 |
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
Topics: Anti-Bacterial Agents; Colony Count, Microbial; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Theoretical; Polymerase Chain Reaction; Protein Binding; Reproducibility of Results; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2007 |
Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
Topics: Amino Acid Substitution; Anti-Infective Agents; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Humans; Indoles; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Quinolones; Staphylococcal Infections; Staphylococcus aureus; Topoisomerase II Inhibitors | 2002 |